Werewolf Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $HOWL in the last 30 days.
See all $HOWL insider activity →Werewolf Therapeutics (HOWL) and Ambros secured $150M in private funding, extending cash runway to 2029. The funds will support clinical trials and potential FDA filings. The merger, pending approval, is a key catalyst but carries risks. Analysts rate HOWL stock as 'Moderate Buy'.
Werewolf Therapeutics (HOWL) will merge with Ambros Therapeutics in an all-stock deal, with a $150M private placement. The combined company, Ambros Therapeutics, will trade as AMBX and focus on CRPS-1 treatments. The deal is expected to close by Q1 2027, pending approvals.
Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal. The combined company will focus on Ambros' neridronate program for CRPS-1 and trade as AMBX. They secured $150M in private placement from healthcare investors. Latham & Watkins advised on the transaction.
Over the past 7 days, alphai's AI scored 3 news stories mentioning HOWL (Werewolf Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent HOWL coverage spans mergers & acquisitions, corporate actions and earnings.
The capital raise provides runway and may boost the stock as the merger progresses.
The merger creates a larger biotech focused on CRPS‑1, potentially boosting pipeline value.
Potential dilution and share price impact from merger and capital raise.
The merger creates a Nasdaq‑listed biotech focused on neridronate, with significant financing to advance Phase 3 trials.
The merger announcement is likely to drive a premium on HOWL shares as investors price in the combined entity.
alphai scores every news story that mentions HOWL with an AI model for sentiment and relevance, and aggregates insider trades from Werewolf Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Werewolf Therapeutics (HOWL) and Ambros secured $150M in private funding, extending cash runway to 2029. The funds will support clinical trials and potential FDA filings. The merger, pending approval, is a key catalyst but carries risks. Analysts rate HOWL stock as 'Moderate Buy'.
2 min readWerewolf Therapeutics (HOWL) will merge with Ambros Therapeutics in an all-stock deal, with a $150M private placement. The combined company, Ambros Therapeutics, will trade as AMBX and focus on CRPS-1 treatments. The deal is expected to close by Q1 2027, pending approvals.
2 min readWerewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal. The combined company will focus on Ambros' neridronate program for CRPS-1 and trade as AMBX. They secured $150M in private placement from healthcare investors. Latham & Watkins advised on the transaction.
2 min readWerewolf Therapeutics (HOWL) and Ambros Therapeutics announced an all-stock merger, creating a Nasdaq-listed biotech firm focused on neridronate for CRPS-1. The combined company, trading as AMBX, secured $150M in financing. Neridronate has FDA designations and is in Phase 3 trials, with results expected in 2028. The merger values Ambros at $500M and Werewolf at $47.5M, with a planned Q1 2027 close. HOWL shares surged 1431.19% in pre-market trading.
2 min readWerewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement • Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved tr
2 min readWerewolf Therapeutics (NASDAQ: HOWL) shares rose 120% premarket after announcing a merger with Ambros Therapeutics and a $150M private placement. The combined company, trading as AMBX, will focus on neridronate for CRPS-1. The merger is expected to close in Q1 2027, with Ambros shareholders owning 71.7% of the new entity.
2 min readWerewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.
2 min readWerewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 14, 2026 (the “Closing”), Werewolf Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with EMD Serono Research & Development Institute Inc. (“EMD”), pursuant to wh
2 min readFactSet says about 75% of S&P 500 firms beat EPS estimates, but only about 60% beat revenue expectations. LSEG research finds earnings forecasts get more accurate as results near, so large surprises are rarer. The article lists nine Q2 companies with notable EPS beats, including HOWL, ABR, PWP, CRI, NWL, MOG-A, MGA, LYB, and NVT, with EPS and beat amounts cited.
7 min readWerewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates Watertown, Mass., July 31, 2026 (GLOBE NEWSWIRE) – Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pione
4 min read
